This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
Willow Biosciences Producing CBG with Scalable Process
Company offers CBG with greater than 99% purity.
Willow Biosciences Inc. says it has successfully developed a scalable process for producing cannabigerol (CBG) with greater than 99 percent purity, no detectable THC and demonstrated production at 500-litre scale.
The company previously announced, in collaboration with its development partner, Albany Molecular Research, Inc., it had commenced a 500-litre pilot scale campaign. In addition to optimizing the production process using its proprietary yeast strain, Willow has developed a high-yielding downstream purification process that provides CBG with greater than 99% purity. This productive strain and simplified downstream process should enable manufacturing in smaller, capital-light, GMP-compliant fermentation production facilities, at a fraction of the cost and environmental footprint of plant cultivation and extraction.